Icon Plc (NASDAQ:ICLR) – KeyCorp decreased their Q1 2019 earnings estimates for shares of Icon in a report issued on Tuesday, January 8th. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings per share of $1.63 for the quarter, down from their previous estimate of $1.66. KeyCorp also issued estimates for Icon’s Q2 2019 earnings at $1.68 EPS, Q3 2019 earnings at $1.72 EPS, Q4 2019 earnings at $1.83 EPS, FY2019 earnings at $6.86 EPS and FY2020 earnings at $7.81 EPS.
Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 24th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.54. Icon had a net margin of 12.88% and a return on equity of 26.08%. The business had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million.
Shares of ICLR stock opened at $135.21 on Thursday. Icon has a 1 year low of $101.22 and a 1 year high of $155.33. The firm has a market cap of $6.69 billion, a P/E ratio of 25.09, a P/E/G ratio of 1.58 and a beta of 0.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.17.
Institutional investors and hedge funds have recently bought and sold shares of the business. Rehmann Capital Advisory Group boosted its stake in Icon by 75.5% during the third quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock worth $64,000 after buying an additional 179 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Icon by 119.7% during the third quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock worth $113,000 after buying an additional 419 shares in the last quarter. Capital Advisors Ltd. LLC acquired a new stake in Icon during the third quarter worth $121,000. Csenge Advisory Group acquired a new stake in Icon during the third quarter worth $150,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Icon in the 3rd quarter valued at $200,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: How to calculate the intrinsic value of a stock
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.